The changing roles of steroid nuclear receptors with prostate cancer progression

    1. Paramita M Ghosh1,2,3
    1. 1Departments of Urology
      2Biochemistry and Molecular Medicine, University of California Davis, Sacramento, California, USA
      3VA Northern California Health Care System, Sacramento, California, USA
    1. Correspondence should be addressed to P M Ghosh; Email: paramita.ghosh{at}ucdmc.ucdavis.edu

    Abstract

    Estrogens were once used for the treatment of prostate cancer (PC). They may still be used in various parts of the world to that effect. Recent developments in the understanding of a role for estrogen receptor β (ERβ) in the development and progression of this disease resurrect the discussion on the intertwined roles of ERβ and the androgen receptor (AR) in promoting PC. A new article by Zellweger et al. in Endocrine-Related Cancer investigates the expression and assesses the activity of ERα and ERβ as well as the AR, in addition to a phosphorylated form of AR in hormone-naïve and castration-resistant PC.

    Keywords
    • Revision received 28 May 2013
    • Accepted 30 May 2013
    • Made available online as an Accepted Preprint 6 June 2013
    | Table of Contents

    This Article

    1. doi: 10.1530/ERC-13-0193 Endocr Relat Cancer 20 C9-C11
    1. Abstract
    2. Full Text
    3. Full Text (PDF)
    4. All Versions of this Article:
      1. ERC-13-0193v1
      2. 20/4/C9 most recent

    Article Metrics

    1. Article Usage Statistics

    New Articles: issue in progress

    1. November 2017, 24 (11)
    1. Current Issue
    1. Alert me to new issues of Endocrine-Related Cancer

    Most